Nigeria secures a $747 million syndicated loan for a controversial highway that will link the nation’s commercial capital to a key coastal city https://t.co/DUu9GYrLz8 ...

Core Viewpoint - The First Trust Rising Dividend Achievers ETF (RDVY) is a smart beta ETF that aims to provide broad exposure to the large-cap value segment of the market, focusing on companies with a history of paying dividends [1][5]. Fund Overview - RDVY was launched on January 7, 2014, and has accumulated over $15.23 billion in assets, making it one of the larger ETFs in its category [1][5]. - The fund is managed by First Trust Advisors and seeks to match the performance of the NASDAQ US Rising Dividend Achievers Index [5]. Cost and Performance - The ETF has an annual operating expense ratio of 0.48%, which is competitive within its peer group [6]. - It offers a 12-month trailing dividend yield of 1.43% [6]. - The ETF has returned approximately 8.19% and is up about 18.06% year-to-date as of July 10, 2025 [9]. Sector Exposure and Holdings - RDVY's largest sector allocation is in Financials, comprising approximately 38.6% of the portfolio, followed by Information Technology and Consumer Discretionary [7]. - Ebay Inc. (EBAY) represents about 2.52% of the fund's total assets, with the top 10 holdings accounting for around 23.33% of total assets under management [8]. Risk Profile - The ETF has a beta of 1.07 and a standard deviation of 19.07% over the trailing three-year period, indicating a medium risk profile [9]. - With approximately 77 holdings, RDVY effectively diversifies company-specific risk [9]. Alternatives - Other ETFs in the large-cap value space include Schwab U.S. Dividend Equity ETF (SCHD) and Vanguard Value ETF (VTV), which have significantly larger asset bases and lower expense ratios [11].

Core Insights - The SPDR S&P Biotech ETF (XBI) is a smart beta ETF launched on January 31, 2006, providing broad exposure to the Health Care ETFs category [1] - XBI is managed by State Street Global Advisors and has over $5.04 billion in assets, making it one of the largest ETFs in the Health Care sector [5] - The ETF aims to match the performance of the S&P Biotechnology Select Industry Index, which is a modified equal weight index representing the biotechnology sub-industry [6] Investment Strategy - Smart beta ETFs like XBI focus on non-cap weighted strategies, selecting stocks based on fundamental characteristics to enhance risk-return performance [3] - The ETF has an annual operating expense ratio of 0.35%, making it one of the least expensive options in its category [7] Sector Exposure and Holdings - XBI's portfolio is entirely allocated to the Healthcare sector, with Insmed Inc (INSM) being the largest holding at approximately 3.29% of total assets [8][9] - The top 10 holdings of XBI account for about 27.56% of its total assets under management [9] Performance Metrics - Year-to-date, XBI has experienced a loss of approximately -2.42%, and over the last 12 months, it is down about -6.86% [11] - The ETF has a beta of 0.86 and a standard deviation of 29.73% over the trailing three-year period, indicating a higher risk profile [11] Alternatives - Other ETFs in the biotechnology space include the First Trust NYSE Arca Biotechnology ETF (FBT) and the iShares Biotechnology ETF (IBB), with assets of $1.03 billion and $5.52 billion respectively [13] - FBT has an expense ratio of 0.54%, while IBB charges 0.45%, providing investors with alternative options [13]

Core Insights - The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) is a smart beta ETF launched on October 9, 2013, providing exposure to the Large Cap Value category [1] - NOBL has accumulated over $11.6 billion in assets, making it one of the larger ETFs in its category [5] - The ETF aims to match the performance of the S&P 500 Dividend Aristocrats Index, which includes companies that have increased dividend payments for at least 25 consecutive years [5] Fund Characteristics - NOBL has an annual operating expense ratio of 0.35%, which is competitive within its peer group [6] - The ETF's 12-month trailing dividend yield is 2.07% [6] - The fund has a beta of 0.84 and a standard deviation of 14.52% over the trailing three-year period, indicating medium risk [10] Sector Exposure and Holdings - The ETF has a significant allocation in the Industrials sector, comprising approximately 23.5% of the portfolio, followed by Consumer Staples and Financials [7] - Emerson Electric Co (EMR) is the largest individual holding at about 1.79% of total assets, with the top 10 holdings accounting for approximately 14.94% of total assets [8] Performance - NOBL has experienced a year-to-date increase of about 10.3% and a total increase of roughly 4.3% [10] - The ETF has traded within a range of $90.85 to $108.47 over the past 52 weeks [10] Alternatives - Other ETFs in the same space include iShares Core Dividend Growth ETF (DGRO) and Vanguard Dividend Appreciation ETF (VIG), with assets of $32.43 billion and $93.11 billion respectively [12] - DGRO has a lower expense ratio of 0.08%, while VIG has an expense ratio of 0.05% [12]

DENVER, July 10, 2025 (GLOBE NEWSWIRE) -- The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a developer, marketer and seller of branded nutritional foods and snacking products, today reported financial results for the thirteen and thirty-nine weeks ended May 31, 2025. The acquisition of Only What You Need, Inc. ("OWYN") was completed on June 13, 2024. Therefore, the Company's year-ago performance for the thirteen and thirty-nine weeks ended May 25, 2024, does not include ...

Core Viewpoint - Pharvaris is advancing its late-stage development of deucrictibant, an oral bradykinin B2 receptor antagonist, targeting unmet needs in bradykinin-mediated diseases, with topline data from the RAPIDe-3 Phase 3 study expected in Q4 2025 and a potential NDA submission in H1 2026 [1][2][4] Group 1: Study and Data - The RAPIDe-3 study has achieved target enrollment, and the topline data announcement is now anticipated in the fourth quarter of 2025 [2] - The study evaluates deucrictibant immediate-release capsules (20 mg) for on-demand treatment of angioedema attacks in approximately 120 participants aged 12 and older, including those with C1 inhibitor deficiency [2][3] - Primary endpoints include time to onset of symptom relief and other measures of symptom resolution and safety [2][3] Group 2: Drug Development - Deucrictibant is being developed in two formulations: an extended-release tablet for prophylactic treatment and an immediate-release capsule for rapid treatment [3][4] - The drug has received orphan drug designation from the FDA and the European Commission for treating bradykinin-mediated angioedema [3] Group 3: Company Overview - Pharvaris aims to provide injectable-like efficacy and placebo-like tolerability through oral therapies for bradykinin-mediated angioedema [4] - The company is conducting multiple pivotal Phase 3 studies, including CHAPTER-3 for prevention and RAPIDe-3 for on-demand treatment of HAE attacks [4]

Core Insights - Happy Belly Food Group Inc. has expanded its franchise agreement with an existing multi-unit franchisee in Alberta from 10 to 15 units for its Heal Wellness brand, which specializes in fresh smoothie bowls and smoothies [1][3][5] - The expansion reflects strong organic support from the franchisee base, indicating a growing interest in multi-unit ownership among existing operators [3][5] - Heal Wellness is recognized as Canada's first national smoothie bowl brand, with a scalable, asset-light model that supports its growth and enhances value for franchise partners and investors [5][6] Company Overview - Happy Belly Food Group Inc. is a leader in acquiring and scaling emerging food brands across Canada [9] - The company has a total of 616 retail locations under contract, which includes development, construction, and operational stages, indicating a robust franchise pipeline [5][6] Brand Performance - Heal Wellness has seen significant growth since its initial five-unit agreement in October 2023, doubling to 10 units by May 2024, and now expanding to 15 units [3][5] - The brand is experiencing increasing brand awareness and customer loyalty, contributing to its expanding national footprint with additional units under construction in Alberta, Ontario, and Prince Edward Island [5][6] Strategic Growth - The company is focused on a strategic blend of organic growth and targeted acquisitions to accelerate the momentum behind Heal Wellness and its broader portfolio [5][6] - By aligning with experienced operators and securing prime real estate, Happy Belly aims to strengthen its long-term fundamentals and deliver sustained growth through 2026 and beyond [6]

Core Insights - The landscape of private higher education in China is experiencing unprecedented challenges and opportunities due to demographic shifts and the emergence of new research-oriented universities [1][2][3]. Group 1: Current State of Private Higher Education - As of June 2025, there are 829 private colleges in China, an increase from 799 the previous year, representing 25.75% of all higher education institutions with over 10 million students enrolled [3][4]. - The growth trend in private colleges is accompanied by a significant increase in vocational education institutions, with 24 new private vocational colleges added, while only 6 new private undergraduate colleges were established [5][6][7]. Group 2: Challenges Faced by Private Colleges - Private colleges are facing a severe enrollment crisis, with many institutions reporting significant shortfalls in student admissions, with some experiencing over 50% of their enrollment targets unmet [12][13]. - The competition from public universities, which are expanding their enrollment and have greater financial support, is intensifying the challenges for private institutions [12][14]. Group 3: Financial Pressures and Responses - Many private higher education companies are experiencing financial difficulties, leading to asset sales and tuition increases as strategies to cope with declining enrollment and revenue [16][19]. - For instance, China Tongcai Education reported a 0.5% decrease in revenue due to reduced tuition income, while other institutions have raised tuition fees significantly to offset financial pressures [16][19][20]. Group 4: Future Directions for Private Higher Education - The future of private colleges may hinge on their ability to enhance educational quality and develop unique characteristics to stand out in a competitive market [24][25]. - New research-oriented private universities, such as West Lake University, are setting high standards and attracting top-tier students, indicating a potential shift in the landscape towards higher quality education [24][25][29].

Financial Performance & Guidance - 2018年公司收入为18.34亿美元[13] - 2018年资本支出为8600万美元[13] - 2018年公司回购股份总额为5.916亿美元[17] - 预计2019年收入在18.7亿美元至19亿美元之间[18] - 预计2019年资本支出在9000万美元至1亿美元之间[18] - 预计2020年收入增长将在2019年的基础上增长3-8%[22] Product Performance - 2018年全球车内自动防眩目后视镜（IEC）的渗透率为31.3%[11] - 2018年全球车外自动防眩目后视镜（OEC）的渗透率为12.6%[11] - 2018年IEC出货量为2965.1万个，同比增长5%[11] - 2018年OEC出货量为1195.4万个，同比增长9%[11]

Group 1 - The focus is on long/short equity strategies, emphasizing deep fundamental analysis to identify undervalued stocks for long positions and overvalued stocks for short positions in global equity markets [1] - Detailed financial models are built using discounted cash flow (DCF), relative valuation, and scenario analysis to assess company fundamentals, growth potential, and risks [1] - High-conviction investment recommendations are delivered through comprehensive research, contributing to alpha generation for the fund [1] Group 2 - Market trends, sector dynamics, and macroeconomic factors are monitored to adjust strategies and optimize portfolio performance in real time [1] - Collaboration with the Portfolio Manager is essential for sizing positions, managing risk exposure, and navigating challenges such as short squeezes or market volatility [1]